Clinical Trials Logo

Systemic Scleroderma clinical trials

View clinical trials related to Systemic Scleroderma.

Filter by:

NCT ID: NCT00278525 Completed - Clinical trials for SYSTEMIC SCLERODERMA

Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma

Start date: September 2005
Phase: Phase 2
Study type: Interventional

Scleroderma is a systemic disorder categorized as an immunologically mediated disease that causes collagen deposition of skin and visceral organs. The molecular pathogenesis of scleroderma has been elusive, although vasculopathy and immune mediated mechanisms are thought to be important. Once extensive cutaneous or visceral disease occurs, prognosis is significantly shorter than the general population. Although various treatments have been tried, none of them seems to have changed the natural history of scleroderma. Standard dose immunosuppressive treatment has been disappointing. Recently, cyclophosphamide at 1-2 mg/kg/day orally or 800-1400 mg intravenous (IV) monthly for 6-9 months has proven effective in treatment of scleroderma alveolitis (1). Recent phase I studies of immunoablation with autologous peripheral blood stem cell transplantation (PBSCT) showed some promising data, but the exact efficacy is undetermined (2,3). We now propose, as a phase II randomized study, autologous unmanipulated PBSCT versus pulse cyclophosphamide in patients with systemic scleroderma.

NCT ID: NCT00004563 Completed - Lung Diseases Clinical Trials

Scleroderma Lung Disease

SLS
Start date: August 1999
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.